Chester County News and Community Website
PLYMOUTH MEETING, PA — INOVIO Pharmaceuticals Inc. will present at two New York investor conferences this week and hold one-on-one meetings with investors, giving the biotechnology company additional opportunities to …
INOVIO Steps Up Investor Outreach at New York Conferences Read More PLYMOUTH MEETING, PA — INOVIO (NASDAQ: INO) narrowed its second-quarter net loss as the biotechnology company moved its lead drug candidate toward an Oct. 30 regulatory decision and raised additional …
INOVIO Cuts Quarterly Loss as FDA Decision Nears Read More PLYMOUTH MEETING, PA — INOVIO (NASDAQ: INO) will report second-quarter 2026 financial results after the market closes Aug. 12 and provide investors with a broader business update later that afternoon …
INOVIO Sets Aug. 12 Earnings Update With Business Review Read More PLYMOUTH MEETING, PA — INOVIO (Nasdaq: INO) moved closer to a potential commercial milestone in China after its licensing partner ApolloBio reported positive Phase 3 results for VGX-3100, an investigational …
INOVIO Partner Reports Phase 3 Success for HPV Therapy in China Read More PLYMOUTH MEETING, PA — INOVIO said existing cash reserves are expected to fund operations into the first quarter of 2027, extending beyond a key FDA decision on its lead therapy …
INOVIO Extends Funding Ahead of Critical FDA Decision Read More PLYMOUTH MEETING, PA — INOVIO (Nasdaq: INO) said it will release its first-quarter 2026 financial results after markets close on Wednesday, May 13, followed by a conference call and webcast …
INOVIO to Report First-Quarter Results on May 13 Read More PLYMOUTH MEETING, PA — INOVIO (Nasdaq: INO) will present new preclinical data on DNA-based protein therapies for hemophilia at the World Federation of Hemophilia World Congress in Kuala Lumpur on …
INOVIO to Present Hemophilia Research at Global Conference Read More PLYMOUTH MEETING, PA — INOVIO (Nasdaq: INO) reported its 2025 financial results and said the U.S. Food and Drug Administration is reviewing its lead drug candidate, INO-3107, for a rare …
INOVIO Reports 2025 Results as FDA Reviews Lead Drug Candidate Read More PLYMOUTH MEETING, PA — INOVIO (Nasdaq: INO) said it will present research on its DNA-based therapies at two upcoming scientific conferences in Europe and the United States.
INOVIO to Present DNA Medicine Data at Two Scientific Conferences Read More PLYMOUTH MEETING, PA — INOVIO and Akeso, Inc. announced a clinical trial collaboration to evaluate a combination immunotherapy as a potential treatment for Glioblastoma, the most common and aggressive form …
INOVIO and Akeso Partner to Study New Glioblastoma Therapy Read More